Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

DSpace/Manakin Repository

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial
 
Koole, Simone N.; Schouten, Philip C.; Hauke, Jan; Kluin, Roel J.C.; Nederlof, Petra; Richters, Lisa K.; Krebsbach, Gabriele; Sikorska, Karolina; Alkemade, Maartje; Opdam, Mark; Schagen van Leeuwen, Jules H.; Schreuder, Henk W.R.; Hermans, Ralph H.M.; de Hingh, Ignace H.J.T.; Mom, Constantijne H.; Arts, Henriette J.G.; van Ham, Maaike; van Dam, Peter; Vuylsteke, Peter; Sanders, Joyce; Horlings, Hugo M.; van de Vijver, Koen K.; Hahnen, Eric; van Driel, Willemien J.; Schmutzler, Rita; Sonke, Gabe S.; Linn, Sabine C.
(2022) International Journal of Cancer, volume 151, issue 8, pp. 1394 - 1404
(Article)
Abstract
The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin to interval cytoreductive surgery improves recurrence-free (RFS) and overall survival (OS) in patients with stage III ovarian cancer. Homologous recombination deficient (HRD) ovarian tumors are usually more platinum sensitive. Since hyperthermia impairs BRCA1/2 protein function, we hypothesized that HRD tumors respond ... read more
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: HIPEC, homologous recombination deficiency, ovarian cancer, Oncology, Cancer Research, Journal Article
DOI: https://doi.org/10.1002/ijc.34124
ISSN: 0020-7136
Publisher: John Wiley & Sons Inc.
Note: Funding Information: These analyses were funded by the Starz Foundation and the Köln Fortune Program. The OVHIPEC clinical trial was funded by the Dutch Cancer Society. Funding Information: Philip Schouten is partner employed by AstraZeneca, with no direct connection to this work. Ignace de Hingh has an unrestricted research grant from Roche and RanD Biotechnology for unrelated research. The grant is payed to the institute. Rita Schmutzler has a grant from Amgen and AstraZeneca, and received honoraria from presentations from AstraZeneca and Janssen‐Cilag. She reports AdBoards from: AstraZenca, GSK, Clovis Oncology and MSD. Gabe Sonke reports consulting work for Biovica ans Seagen. Research support in paid to the institution from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen. Sabine Linn has been an advisory board member for AstraZeneca, Cergentis, IBM, Novartis, Pfizer, Roche and Sanofi, and has received unrestricted institutional research support of unrestricted educational funding from Agendia, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eurocept Pharmaceuticals, Genentech, Immunomedics, Merck, Roche, Sanofi and TESARO. Sabine Linn has a patent application pending on a BRCA‐like ovarian cancer classifier. All other authors declare no conflicts of interest. Funding Information: We acknowledge the NKI-AVL Core Facility Molecular Pathology & Biobanking (CFMPB) and the Genomic Core Facility database for lab support and collaboration, in particular S. Broersen, L. Braaf, S. Cornelissen, A. Broeks, C. van Steenis, R. Kerkhoven, E. Holman and J. Overwater for support. We thank R. Rahman for technical support. We would like to thank the Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), in particular Mrs. D.J. Jenner and the HEBON study participants for the germline-status data delivery on behalf of HEBON. We thank the nationwide network and registry of histo- and cytopathology in the Netherlands “PALGA: Dutch Pathology Registry,” for national collection and distribution of tissue samples. We thank the Starz Foundation for unrestricted research support for this study. “Peter Vuylsteke's research was supported by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institute of Health (NIH) under award number UL1TR003017. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Funding Information: We acknowledge the NKI‐AVL Core Facility Molecular Pathology & Biobanking (CFMPB) and the Genomic Core Facility database for lab support and collaboration, in particular S. Broersen, L. Braaf, S. Cornelissen, A. Broeks, C. van Steenis, R. Kerkhoven, E. Holman and J. Overwater for support. We thank R. Rahman for technical support. We would like to thank the Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), in particular Mrs. D.J. Jenner and the HEBON study participants for the germline‐status data delivery on behalf of HEBON. We thank the nationwide network and registry of histo‐ and cytopathology in the Netherlands “PALGA: Dutch Pathology Registry,” for national collection and distribution of tissue samples. We thank the Starz Foundation for unrestricted research support for this study. “Peter Vuylsteke's research was supported by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institute of Health (NIH) under award number UL1TR003017. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Publisher Copyright: © 2022 UICC.
(Peer reviewed)